
PVLA Stock Forecast & Price Target
PVLA Analyst Ratings
Bulls say
Palvella Therapeutics is a biopharmaceutical company with a strong pipeline and a focus on rare skin diseases. Their promising treatment for miLMs and plans for US NDA filing in 2026 are key factors contributing to a positive outlook. With a European patent in hand and a strong management team, their stock price is estimated to reach $240 in the future.
Bears say
Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare skin diseases and vascular malformations. However, due to the unproven nature of the company's main technology platform, the negative results from clinical trials of its lead product candidate, delays and added costs associated with clinical development, and potential challenges to its patents, there is a high level of uncertainty and risk involved in investing in Palvella. Additionally, the company's lack of revenue and profitability makes it difficult to accurately forecast its future potential and creates a reliance on external financing which could lead to shareholder dilution.
This aggregate rating is based on analysts' research of Palvella Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PVLA Analyst Forecast & Price Prediction
Start investing in PVLA
Order type
Buy in
Order amount
Est. shares
0 shares